SynthesisFrontiers in oncology2025
The effect of hormone replacement therapy on cervical cancer risk in perimenopausal women: a systematic review and meta-analysis of observational studies.
Synthesis in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Hormone therapy and the risk of central nervous system tumors in women: a systematic review and meta-analysis.Journal of neuro-oncology · 2026Pooled it
- A Randomized Controlled Trial on the Safety and Cognitive Benefits of a Novel Functional Drink from a Purple Waxy Corn Byproduct in Peri- and Postmenopausal Women.Antioxidants (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Hormone replacement therapy (HRT) alleviates menopausal symptoms in perimenopausal women and help improve their quality of life, but its increased risk of cervical cancer (CC) remains to be evaluated. Methods: A system review and meta-analysis was conducted to retrieve literature related to HRT and CC risk by searching Pubmed, Embase, Science Direct, Web of Science, and Google Scholar databases. After screening the literature according to inclusion criteria and assessing the risk of bias using the Newcastle Ottawa Scale, the odd ratio (OR) values of HRT relative to CC were pooled. Results: A total of 9 articles were included in this study, including 5 cohort studies and 4 case control studies. The sample size of perimenopausal women in the literature ranged from 60 to 584,742. The overall quality of the literature was good. The meta-analysis results showed that HRT (current and persist use) had a reduced risk for CC (OR=0.70, 95% confidence interval (CI) [0.58, 0.85]), an increased risk for any cytological abnormality related to CC (OR=1.38, 95% CI [1.22, 1.55]), also an increased risk for adenocarcinoma of CC (OR=1.82, 95% CI [0.91,3.65]), but a decreased risk for squamous cell carcinoma of CC (OR=0.74, 95% CI [0.57, 0.96]). The subtype was a significant source of heterogeneity in this meta-analysis. Conclusion: HRT does not increase the overall risk of cervical cancer, but it increases the risk of cervical adenocarcinoma subtype and is associated with the risk of cancer-related cytological lesions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.